Horizon Pharma (HZNP) Tops Q2 EPS by 12c
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/17/2026
- S&P on track for muted open as Middle East tensions weigh; AI stocks boost Nasdaq
- Trump threatens to bomb Oman over Iran stance
- Why this Wall Street strategist says the "trade is long gold"
- U.S. EV market shows signs of bottoming out: Bernstein
- Micron rises as White House presses Apple to avoid Chinese memory chips
- L3Harris CEO steps down amid conduct review, shares drop
- Reddit leads social media platforms in revenue growth per user
- Northland Upgrades Astera Labs (ALAB) to Outperform, 'Right Time, Customers, and Products'
- Fulcrum Therapeutics to merge with Slate Medicines in all-stock deal
- Piper Sandler Starts SoFi Technologies (SOFI) at Overweight
Horizon Pharma (HZNP) PT Bumped to $30 at BMO Capital Amid 'Very Solid' Q2
August 8, 2016 3:44 PM EDTBMO Capital analyst Gary Nachman reiterated an Outperform rating and bumped his price target on Horizon Pharma (NASDAQ: HZNP) to $30.00 (from $29.00) following "very solid" 2Q with revenue of $257mn vs. BMO/consensus of $235mn/235mn. EPS was $0.62 vs. BMO/consensus of $0.50/0.50 using the old tax... More
Piper Jaffray Remains Bullish on Horizon Pharma (HZNP) Following 'Strong' Q2, PT Trimmed to $33
August 8, 2016 12:33 PM EDTPiper Jaffray analyst David Amsellem reiterated an Overweight rating on Horizon Pharma (NASDAQ: HZNP) but trimmed his price target to $33.00 (from $34.00) following "strong" Q2 results. The firm is remaining bullish on the name.
Amsellem commented, "Horizon reported 2Q16 non-GAAP diluted EPS of $0.56... More
